Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEO NASDAQ:IMTX NASDAQ:PURR NASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$6.18+9.2%$5.60$4.00▼$7.54$322.59M1.351.13 million shs2.20 million shsIMTXImmatics$10.13+6.0%$10.55$5.05▼$12.41$1.28B1.3484,774 shs753,500 shsPURRHyperliquid Strategies$7.87-7.1%$7.88$3.01▼$11.62$1.22B1.6417.94 million shs10.21 million shsSDGRSchrodinger$16.25-6.6%$13.85$10.94▼$23.75$1.28B1.641.36 million shs2.67 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics+9.19%+8.04%+6.92%+34.93%+8.80%IMTXImmatics+5.96%+2.01%-11.99%+1.20%+88.29%PURRHyperliquid Strategies-7.08%-3.32%-21.22%+53.41%+786,999,900.00%SDGRSchrodinger-6.56%+8.05%+6.91%+40.69%-19.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$6.18+9.2%$5.60$4.00▼$7.54$322.59M1.351.13 million shs2.20 million shsIMTXImmatics$10.13+6.0%$10.55$5.05▼$12.41$1.28B1.3484,774 shs753,500 shsPURRHyperliquid Strategies$7.87-7.1%$7.88$3.01▼$11.62$1.22B1.6417.94 million shs10.21 million shsSDGRSchrodinger$16.25-6.6%$13.85$10.94▼$23.75$1.28B1.641.36 million shs2.67 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics+9.19%+8.04%+6.92%+34.93%+8.80%IMTXImmatics+5.96%+2.01%-11.99%+1.20%+88.29%PURRHyperliquid Strategies-7.08%-3.32%-21.22%+53.41%+786,999,900.00%SDGRSchrodinger-6.56%+8.05%+6.91%+40.69%-19.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 2.67Moderate Buy$19.00207.44% UpsideIMTXImmatics 2.63Moderate Buy$20.80105.33% UpsidePURRHyperliquid Strategies 2.50Moderate Buy$9.2517.53% UpsideSDGRSchrodinger 2.33Hold$20.2524.62% UpsideCurrent Analyst Ratings BreakdownLatest ABEO, IMTX, PURR, and SDGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026ABEOAbeona Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)6/23/2026IMTXImmatics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)6/12/2026PURRHyperliquid Strategies Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.756/9/2026IMTXImmatics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)6/3/2026PURRHyperliquid Strategies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/28/2026ABEOAbeona Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.005/20/2026PURRHyperliquid Strategies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (D)5/20/2026PURRHyperliquid Strategies Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.45 ➝ $9.755/19/2026IMTXImmatics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.005/14/2026SDGRSchrodinger Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$19.00 ➝ $17.005/11/2026PURRHyperliquid Strategies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$6.00 ➝ $8.00(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$5.82M60.52N/AN/A$2.94 per share2.10IMTXImmatics$54.60M24.87N/AN/A$4.09 per share2.48PURRHyperliquid Strategies$1M1,136.82N/AN/A$1.52 per share5.18SDGRSchrodinger$255.87M4.69N/AN/A$4.94 per share3.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics$71.18M$0.976.37N/AN/AN/A-53.98%-38.52%8/13/2026 (Estimated)IMTXImmatics-$222.26M-$1.99N/AN/AN/A-572.35%-47.36%-39.35%8/12/2026 (Estimated)PURRHyperliquid Strategies-$16.01M-$7.37N/AN/AN/AN/A-56.04%-52.22%N/ASDGRSchrodinger-$103.26M-$1.41N/AN/AN/A-40.61%-30.85%-15.32%8/5/2026 (Estimated)Latest ABEO, IMTX, PURR, and SDGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ABEOAbeona Therapeutics-$0.33-$0.30+$0.03-$0.30$4.57 million$8.72 million5/12/2026Q1 2026IMTXImmatics-$0.42-$0.50-$0.08-$0.50$9.79 million$8.81 million5/7/2026Q3 2026PURRHyperliquid StrategiesN/A$1.01N/A$1.01N/A$2.63 million5/5/2026Q1 2026SDGRSchrodinger-$0.56-$0.81-$0.25-$0.81$47.57 million$58.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/APURRHyperliquid StrategiesN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.035.895.70IMTXImmaticsN/A8.788.78PURRHyperliquid StrategiesN/A18.2318.22SDGRSchrodingerN/A2.742.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%IMTXImmatics64.41%PURRHyperliquid Strategies9.45%SDGRSchrodinger79.05%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics7.10%IMTXImmaticsN/APURRHyperliquid Strategies8.48%SDGRSchrodinger10.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9056.99 million52.95 millionOptionableIMTXImmatics260134.07 millionN/AOptionablePURRHyperliquid StrategiesN/A144.45 million132.20 millionN/ASDGRSchrodinger79073.82 million66.37 millionOptionableABEO, IMTX, PURR, and SDGR HeadlinesRecent News About These CompaniesA Look at Schrodinger Inc (SDGR) After 6.6% Decline -- GF Value $26.32 vs Price $16.253 hours ago | gurufocus.comWhat Does Schrodinger Inc (SDGR)’s 2026 Outlook Reveal?June 23, 2026 | finance.yahoo.comA Look at Schrodinger Inc (SDGR) After 6.9% Gain -- GF Value $26.55 vs Price $14.15May 28, 2026 | gurufocus.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 22, 2026 | businesswire.comSchrödinger Balances Growth and Losses in Earnings CallMay 20, 2026 | tipranks.com7 Healthcare AI Stocks Under $50 With Huge Upside PotentialMay 18, 2026 | 247wallst.comSchrödinger, Inc. (SDGR) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comEarnings Update: Schrödinger, Inc. (NASDAQ:SDGR) Just Reported And Analysts Are Trimming Their ForecastsMay 8, 2026 | finance.yahoo.comSchrödinger (SDGR) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comA Look At Schrödinger (NasdaqGS:SDGR) Valuation After Q1 Earnings And Hosted AI Software PushMay 6, 2026 | finance.yahoo.comSchrödinger, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 6, 2026 | seekingalpha.comSchrödinger, Inc. (SDGR) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comSchrödinger Earnings Call: Growth Now, Profits LaterMay 5, 2026 | tipranks.comSchrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue EstimatesMay 5, 2026 | zacks.comSchrödinger Reports First Quarter 2026 Financial ResultsMay 5, 2026 | businesswire.comHere’s What the Street Thinks About Schrödinger (SDGR)May 5, 2026 | insidermonkey.comSchrodinger: AI Threat Is Looming Large (Rating Downgrade)April 22, 2026 | seekingalpha.comSchrödinger to Announce First Quarter 2026 Financial Results on May 5April 21, 2026 | businesswire.comWhat’s Schrodinger Inc (SDGR) Working Out with Anthropic?April 19, 2026 | finance.yahoo.comSchrodinger (NASDAQ:SDGR) CFO Sells $10,761.00 in StockApril 18, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABEO, IMTX, PURR, and SDGR Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$6.18 +0.52 (+9.19%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$6.21 +0.03 (+0.52%) As of 06/30/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Immatics NASDAQ:IMTX$10.13 +0.57 (+5.96%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$10.12 -0.01 (-0.05%) As of 06/30/2026 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Hyperliquid Strategies NASDAQ:PURR$7.87 -0.60 (-7.08%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$7.93 +0.06 (+0.75%) As of 06/30/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc., is based in NEW YORK.Schrodinger NASDAQ:SDGR$16.25 -1.14 (-6.56%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$16.32 +0.07 (+0.43%) As of 06/30/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
